



PRESS RELEASE

FOR IMMEDIATE RELEASE

**12 MAY, 2008**

**PHARMACY CHAIN 36.6 ANNOUNCES THE SALE OF EMC**

12 May 2008, MOSCOW – OAO Pharmacy Chain 36.6 [MMBB: RU14APTK1007; PTC: APTK] announces the complete sale of its Healthcare business unit - the European Medical Center (EMC) group of companies to Goldencorp Enterprises Ltd. (BVI). The sale affects all companies making up the unit including general medical care clinic and hospital\* (European Medical Center), dental clinic (European Dental Center) and clinical laboratory. The total enterprise value is USD 110 million. The proceeds of this transaction will be available to the Company by June 1, 2008.

Jere Calmes, President, OAO Pharmacy Chain 36 commented on the sale:

"We are very pleased with the timely execution and valuation achieved during the sale process. This transaction is 100% in line with the Company's stated strategy of divesting non core operations to focus on its leading pharmaceutical retail business. The sale generated significant interest from the potential investors which allowed us to close the transaction during an extremely short period of time. The terms of the transaction were unanimously supported by the Company's Board of Directors. I'd like to express my gratitude to all team members and partners for successfully achieving this key deliverable of our 2008 funding strategy. All of the proceeds from the sale will be used to finance the current operations of the retail business."

EMC is a unique, western-type clinic based in Moscow with an unrivaled, leading position in the premium segment of the Moscow market for health services. It provides a full spectrum of out-patient and in-patient medical services with more than 57'000 admissions and more than 25'000 customers in 2007. According to unaudited management IFRS accounts EMC sales in 2007 reached USD 25.9 million.

Renaissance Capital acted as a financial advisor of the transaction and Aquila Capital Group acted as financial advisor to the purchaser.

---

\* *The full service hospital on Orlov pereulok is currently under construction, expected to open in 2009.*

###

*For more information, please contact:*

**Maxim Arkhipov,**  
*Director, Corporate Finance and Investor  
Relations*

*arkhipov@oao366.ru  
Tel. (+7495) 797 86 86  
ext. 1763*

*Or see our website:*

[www.pharmacychain366.ru](http://www.pharmacychain366.ru)

*Notes to the editor:*

*Pharmacy Chain 36.6 is the first public national health and beauty retailer listed on the "B" list on the RTS (ticker: APTK) and off-list on the MICEX. The Company's market capitalization as of May 08, 2008 totaled USD 403.75 million (according to RTS). As of December 31, 2007 Pharmacy Chain 36.6 operated 1,224 stores in 29 regions and 90 cities in Russia.*

*OAO Veropharm, the company's generics subsidiary, is one of Russia's top five manufacturers (according to Pharmexpert research). Veropharm's shares are traded in the "B" list on the RTS (ticker: VRPH) and off-list on MICEX (ticker: VRFM). OAO Veropharm's market capitalization of May 08, 2008 was USD 545 million (according to RTS).*

*ZAO Apteki 36.6 is one of the founding members of the Russian Association of Pharmacy Chains (RAPC). Pharmacy Chain 36.6 is a participating member of the international retailers' organizations - NRF and NACDS. Pharmacy Chain 36.6 and its subsidiaries employ over 12,000 people.*

---

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION AND IS NOT AN OFFER TO SELL OR AN INVITATION TO MAKE OFFERS TO PURCHASE ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document should not be considered a public offering of securities in the United States. Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933 as amended (the "Securities Act") and may not be offered or sold in the United States or to US persons.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom and (b) persons in the United Kingdom who have (i) professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (the "Order") or (ii) high net worth companies and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49(2) of the Order (all such persons specified in clauses (a) and (b) and together being referred to as "relevant persons"). Any securities referred to in this press release and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.